PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31903460-6 2020 The involvement of Akt/Hif1alpha/VEGF dependent signal cascading and its down-regulation with a pro-apoptotic drug Dox and an anti-angiogenic agent Gen was evident as demonstrated by an in silico docking study and subsequently proven by RT-PCR and western blotting. Genistein 148-151 vascular endothelial growth factor A Homo sapiens 33-37 30743203-10 2019 After combining with NF-kappaB blocker BAY 11-7082, the effect of genistein down-regulate the expression of TNF-alpha and VEGFA was attenuated in HaCaT cells. Genistein 66-75 vascular endothelial growth factor A Homo sapiens 122-127 32440504-0 2020 Genistein inhibits angiogenesis developed during rheumatoid arthritis through the IL-6/JAK2/STAT3/VEGF signalling pathway. Genistein 0-9 vascular endothelial growth factor A Homo sapiens 98-102 32440504-6 2020 Results: GEN dose-dependently inhibited the expression and secretion of interleukin (IL)-6 and VEGF, as well as the nucleus translocation of Signal transducer and activator of transcription 3 (STAT3) in MH7A. Genistein 9-12 vascular endothelial growth factor A Homo sapiens 95-99 32440504-8 2020 Conclusion: GEN inhibits IL-6-induced VEGF expression and angiogenesis partially through the Janus kinase 2 (JAK2)/STAT3 pathway in RA, which has provided a novel insight into the antiangiogenic activity of GEN in RA. Genistein 12-15 vascular endothelial growth factor A Homo sapiens 38-42 21132400-0 2012 Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation. Genistein 16-25 vascular endothelial growth factor A Homo sapiens 35-39 27076627-6 2016 Ovarian cancer-associated VEGF was inhibited by treatment with bevacizumab and genistein; conditioned medium was collected, and CD1d-mediated NKT-cell responses were assayed by ELISA. Genistein 79-88 vascular endothelial growth factor A Homo sapiens 26-30 28259980-0 2017 Genistein decreases A549 cell viability via inhibition of the PI3K/AKT/HIF-1alpha/VEGF and NF-kappaB/COX-2 signaling pathways. Genistein 0-9 vascular endothelial growth factor A Homo sapiens 82-86 28125877-0 2016 Genistein Suppression of Matrix Metalloproteinase 2 (MMP-2) and Vascular Endothelial Growth Factor (VEGF) Expression in Mesenchymal Stem Cell Like Cells Isolated from High and Low Grade Gliomas Objective: Brain tumors cause great mortality and morbidity worldwide, and success rates with surgicaltreatment remain very low. Genistein 0-9 vascular endothelial growth factor A Homo sapiens 64-98 28125877-0 2016 Genistein Suppression of Matrix Metalloproteinase 2 (MMP-2) and Vascular Endothelial Growth Factor (VEGF) Expression in Mesenchymal Stem Cell Like Cells Isolated from High and Low Grade Gliomas Objective: Brain tumors cause great mortality and morbidity worldwide, and success rates with surgicaltreatment remain very low. Genistein 0-9 vascular endothelial growth factor A Homo sapiens 100-104 28125877-3 2016 Here weassessed the effects of genistein on the expression of MMP-2 and VEGF in low and high grade gliomas in vitro. Genistein 31-40 vascular endothelial growth factor A Homo sapiens 72-76 28125877-8 2016 Genistein caused a4.7-fold reduction in VEGF transcript in high grade glioma cells (P value> 0.05) but no effects were evident in lowgrade glioma cells. Genistein 0-9 vascular endothelial growth factor A Homo sapiens 40-44 21132400-4 2012 In the present experiment, we chose cultured human umbilical vein endothelial cells (HUVECs), which have a considerable role in tumor angiogenesis formation, to explore the influence of genistein on VEGF-stimulated endothelial cell activation and the underlying mechanism. Genistein 186-195 vascular endothelial growth factor A Homo sapiens 199-203 21132400-6 2012 Treatment of ECs with genistein induced VEGF-loaded endothelial apoptosis by inhibiting production and activity of matrix metalloproteinases (MMPs). Genistein 22-31 vascular endothelial growth factor A Homo sapiens 40-44 21132400-7 2012 In addition, exposure to genistein decreased activation of JNK and p38, not ERK-1/2, induced by VEGF. Genistein 25-34 vascular endothelial growth factor A Homo sapiens 96-100 21132400-8 2012 Collectively, our findings suggested that the inhibition of PTK activity and MAPK activation and the decrease in MMPs production and activity by genistein interrupt VEGF-stimulated endothelial cell activation, which thereby may represent a mechanism that would explain the anti-angiogenesis effect of genistein and its cancer-protective function. Genistein 145-154 vascular endothelial growth factor A Homo sapiens 165-169 21132400-8 2012 Collectively, our findings suggested that the inhibition of PTK activity and MAPK activation and the decrease in MMPs production and activity by genistein interrupt VEGF-stimulated endothelial cell activation, which thereby may represent a mechanism that would explain the anti-angiogenesis effect of genistein and its cancer-protective function. Genistein 301-310 vascular endothelial growth factor A Homo sapiens 165-169 20211058-8 2010 The results of flow cytometry showed that: after SW480 cells were treated with 0, 20, 40, 80 microg/ml genistein for 48 h, the FI values of PCNA were 1.49 +/- 0.02, 1.28 +/- 0.04, 1.14 +/- 0.03, and 0.93 +/- 0.08; the FI values of VEGF were 1.75 +/- 0.02, 1.34 +/- 0.06, 1.32 +/- 0.04, and 1.23 +/- 0.04; the fluorescence index (FI) values of p21 were 1.26 +/- 0.05, 1.36 +/- 0.06, 1.61 +/- 0.03, and 1.73 +/- 0.03, respectively. Genistein 103-112 vascular endothelial growth factor A Homo sapiens 231-235 22284780-13 2012 Recent studies further indicate that apigenin, genistein, kaempferol, luteolin, and quercetin potently inhibit VEGF production and suppress ovarian cancer cell metastasis in vitro. Genistein 47-56 vascular endothelial growth factor A Homo sapiens 111-115 21078540-5 2011 The mechanism is at least partially due to the suppressive effect of genistein both on the proper and ATO-induced Akt activation, and on the activity of NF-kappaB, and the latter correlated with the suppression of NF-kappaB regulated gene products, including cyclin D1, Bcl-xL, Bcl-2, c-myc, COX-2, and VEGF. Genistein 69-78 vascular endothelial growth factor A Homo sapiens 303-307 21898109-4 2012 Genistein, a crucial non-nutrient component in soybean, exhibits anti-cancer effects by inhibiting protein tyrosine kinase that is involved in up-regulation of VEGF. Genistein 0-9 vascular endothelial growth factor A Homo sapiens 160-164 21898109-7 2012 We further explored the role of genistein on countering the ATRA-induced VEGF expression. Genistein 32-41 vascular endothelial growth factor A Homo sapiens 73-77 21898109-10 2012 Finally, expression of VEGF (both mRNA and protein) was diminished in A549 cells exposed to both ATRA and genistein. Genistein 106-115 vascular endothelial growth factor A Homo sapiens 23-27 21898109-11 2012 In conclusion, our results demonstrate that genistein effectively enhances anti-cancer effects of ATRA, particularly, by countering the ATRA-induced up-regulation of VEGF. Genistein 44-53 vascular endothelial growth factor A Homo sapiens 166-170 20354770-7 2010 RESULTS: We found that genistein inhibited cell growth accompanied by induction of apoptosis with concomitant attenuation of FoxM1 and its downstream genes, such as survivin, cdc25a, MMP-9, and VEGF, resulting in the inhibition of pancreatic cancer cell invasion. Genistein 23-32 vascular endothelial growth factor A Homo sapiens 194-198 18026817-5 2008 AngII-VEGF induction was inhibited by the tyrosine kinase inhibitor genistein, suggesting a mitogen-activated protein kinase signaling mechanism. Genistein 68-77 vascular endothelial growth factor A Homo sapiens 6-10 19091461-8 2009 In conclusion, the terazosin/genistein combination was more effective in inhibiting cell growth and VEGF expression as well as inducing apoptosis of the metastatic, androgen-independent prostate cancer cell line, DU-145, than either alone. Genistein 29-38 vascular endothelial growth factor A Homo sapiens 100-104 19167346-5 2009 In addition, the activity of DCs to internalize VEGF was abolished by neutralizing antibody against VEGF receptor-1 (Flt-1) and inhibitors of endocytosis such as carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and genistein. Genistein 215-224 vascular endothelial growth factor A Homo sapiens 48-52 11804877-6 2002 Likewise, at-RA-mediated VEGF expression was completely blocked in the presence of genistein, an inhibitor for tyrosine kinases. Genistein 83-92 vascular endothelial growth factor A Homo sapiens 25-29 19005980-10 2008 Genistein, quercetin, and luteolin have shown strong inhibition to cell proliferation and VEGF expression of human ovarian cancer cells, and they show promising in the prevention of ovarian cancers. Genistein 0-9 vascular endothelial growth factor A Homo sapiens 90-94 17142033-5 2007 Genistein (5-50 muM) significantly inhibited the growth of human umbilical vein endothelial cells (HUVECs) in control media when stimulated by supplemental VEGF or when cultured in hypoxia-exposed PC-3 prostate adenocarcinoma cell conditioned media. Genistein 0-9 vascular endothelial growth factor A Homo sapiens 156-160 17142033-7 2007 Genistein (10-50 muM) caused significant inhibition of basal VEGF expression and hypoxia-stimulated VEGF expression in both human prostate cancer PC-3 cells and HUVECs based on semiquantitative reverse transcription-polymerase chain reaction (P<.05). Genistein 0-9 vascular endothelial growth factor A Homo sapiens 61-65 17142033-7 2007 Genistein (10-50 muM) caused significant inhibition of basal VEGF expression and hypoxia-stimulated VEGF expression in both human prostate cancer PC-3 cells and HUVECs based on semiquantitative reverse transcription-polymerase chain reaction (P<.05). Genistein 0-9 vascular endothelial growth factor A Homo sapiens 100-104 17142033-8 2007 In parallel, VEGF secretion by PC-3 cells quantitated by enzyme-linked immunosorbent assay was significantly (P<.05) reduced by genistein (10-50 muM). Genistein 131-140 vascular endothelial growth factor A Homo sapiens 13-17 17142033-9 2007 Furthermore, genistein (10-50 muM) significantly (P<.05) reduced PC-3 nuclear accumulation of hypoxia-inducible factor-1alpha, the principle transcription factor that regulates VEGF expression in response to hypoxia. Genistein 13-22 vascular endothelial growth factor A Homo sapiens 180-184 17142033-10 2007 Expression of the VEGF receptor fms-like tyrosine kinase-1, but not kinase insert domain-containing kinase, in HUVECs was also reduced (P<.05) by genistein (10-50 muM). Genistein 149-158 vascular endothelial growth factor A Homo sapiens 18-22 17142033-11 2007 These observations support the hypothesis that genistein may inhibit prostate tumor angiogenesis through the suppression of VEGF-mediated autocrine and paracrine signaling pathways between tumor cells and vascular endothelial cells. Genistein 47-56 vascular endothelial growth factor A Homo sapiens 124-128 17059009-6 2006 The expession level of NF-kappaB (P65) protein decreased obviously in HO-8910PM cells treated with 25 approximately 100 micromol/L genistein for 24 hours, and the effect appeared in the experssion of VEGF. Genistein 131-140 vascular endothelial growth factor A Homo sapiens 200-204 16673816-14 2006 The inhibition of PC-3 cells by genistein and that of LNCaP cells by genistein and daidzein may be via Akt pathway that is repressed by PTEN gene, which subsequently down-regulates the expression of AR and VEGF genes. Genistein 32-41 vascular endothelial growth factor A Homo sapiens 206-210 16673816-14 2006 The inhibition of PC-3 cells by genistein and that of LNCaP cells by genistein and daidzein may be via Akt pathway that is repressed by PTEN gene, which subsequently down-regulates the expression of AR and VEGF genes. Genistein 69-78 vascular endothelial growth factor A Homo sapiens 206-210 15323430-3 2004 We found that the expression of VEGF, MMP-2,9 and uPA in MCF-7/HER-2 cells were highter than that in MCF-7 cells, those angiogenesis related factors expression in MCF-7/HER-2 cells significantly decreased after treatment with genistein. Genistein 226-235 vascular endothelial growth factor A Homo sapiens 32-36 15323430-4 2004 Genistein could inhibit expression of angiogenesis-related factors VEGF, MMP-2,9 and uPA in HER-2/neu-overexpressing breast cancer cells, and this may be part of molecular mechanism of its anti-angiogenesis in HER-2/neu-overexpressing breast cancer. Genistein 0-9 vascular endothelial growth factor A Homo sapiens 67-71 14692041-0 2004 Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Genistein 27-36 vascular endothelial growth factor A Homo sapiens 154-158 14692041-3 2004 Among the biologic effects of Genistein are the inhibition of tyrosine kinases and the inhibition of hypoxic activation of hypoxia-inducible factor-1 (HIF-1), one of the main regulators of VEGF gene expression. Genistein 30-39 vascular endothelial growth factor A Homo sapiens 189-193 14692041-8 2004 RESULTS: VEGF protein secretion was dose-dependently suppressed with increasing doses of Genistein. Genistein 89-98 vascular endothelial growth factor A Homo sapiens 9-13 14692041-10 2004 Northern blot analysis indicated that VEGF mRNA expression decreased upon treatment with Genistein, both under normoxic and hypoxic culture conditions. Genistein 89-98 vascular endothelial growth factor A Homo sapiens 38-42 12761886-10 2003 In conclusion, these data suggest that genistein, apigenin, and 3-hydroxyflavone inhibit in vitro angiogenesis, in part via preventing VEGF/bFGF-induced MMP-1 and uPA expression and the activation of pro-MMP-2, and via modulating their inhibitors, TIMP-1 and -2, and PAI-1. Genistein 39-48 vascular endothelial growth factor A Homo sapiens 135-139 17915218-8 2007 In both ARPE-19 and primary RPE cells, the response to VEGF was blocked by pretreatment with the relatively selective VEGF-R2 antagonists, SU5416 or ZM323881, or the protein tyrosine kinase inhibitor, genistein. Genistein 201-210 vascular endothelial growth factor A Homo sapiens 55-59 15498380-8 2004 The levels of HIF-1alpha and VEGF protein expression in SW480 cells were significantly higher in the hypoxia group than in the normoxia group (P < 0.01, P < 0.05, respectively) and hypoxia/genistein group (P < 0.01, P < 0.05, respectively). Genistein 195-204 vascular endothelial growth factor A Homo sapiens 29-33 12811578-3 2003 We therefore evaluated the effects of green tea, its major component epigallocatechin-3-gallate (EGCG) and an isoflavone derived from soybean (genistein) on the release of VEGF and IL-8 by activated normal human keratinocytes (NHK). Genistein 143-152 vascular endothelial growth factor A Homo sapiens 172-176 11875741-5 2002 Northern blot analyses revealed that, among the five agents examined, genistein had a strong inhibitory effect on expression of vascular endothelial growth factor mRNA and basic fibroblast growth factor mRNA. Genistein 70-79 vascular endothelial growth factor A Homo sapiens 128-162 11875741-8 2002 Genistein also inhibited both vascular endothelial growth factor mRNA and basic fibroblast growth factor mRNA expression after treatment with epidermal growth factor and hypoxia. Genistein 0-9 vascular endothelial growth factor A Homo sapiens 30-64 11875741-9 2002 These findings suggest that one of the mechanisms of the inhibition of angiogenesis by genistein is suppression of the expression of the angiogenic factors vascular endothelial growth factor and basic fibroblast growth factor in renal cell carcinoma. Genistein 87-96 vascular endothelial growth factor A Homo sapiens 156-190 11678207-3 2001 The tyrosine kinase inhibitor genistein and AP-1 inhibitor curcumin significantly blocked TGF-beta induction of VEGF expression while SP-1 and MKK1 inhibitors did not. Genistein 30-39 vascular endothelial growth factor A Homo sapiens 112-116 11926591-4 2002 The signalling mechanism of the COX isoform expressed in endothelial cells activated with VEGF will be also investigated using the tyrosine kinase inhibitor, genistein, and protein kinase C inhibitor, staurosporine. Genistein 158-167 vascular endothelial growth factor A Homo sapiens 90-94 11926591-9 2002 Interestingly, the increased COX-2 protein and activity in response to VEGF (10 ng/ml) was inhibited by the tyrosine kinase inhibitor, genistein (0.05-5 microg/ml), but not by the protein kinase C inhibitor, staurosporine (0.1-10 ng/ml). Genistein 135-144 vascular endothelial growth factor A Homo sapiens 71-75 12391545-6 2002 VEGF secretion was inhibited by cycloheximide (85%) and the specific inhibitors of protein tyrosine kinase, genistein (71+/-0.74 and 55+/-4.90%) and mitogen-activated protein (MAP)-kinase, PD098059 (82+/-2.0 and 59+/-6.7%) in A375 and J82 cells respectively. Genistein 108-117 vascular endothelial growth factor A Homo sapiens 0-4 11352660-8 2001 VEGF-stimulated proliferation of BeWo cells was inhibited by the tyrosine kinase inhibitor genistein but increased by PD98059. Genistein 91-100 vascular endothelial growth factor A Homo sapiens 0-4 11778268-8 2000 Furthermore, genistein inhibited angiogenesis as shown by decreased vessel density and decreased production and release of VEGF and TGF-beta 1. Genistein 13-22 vascular endothelial growth factor A Homo sapiens 123-127 10397456-3 1998 Irradiating the cells with 15 Gy X-rays significantly increased the mRNA expression up to 2.5-fold of control at a post-irradiation time of 16-24 h. The induction of VEGF mRNA by X-ray irradiation was completely blocked by treating cells with either genistein (Src tyrosine kinase inhibitor) or H7 (protein kinase C inhibitor). Genistein 250-259 vascular endothelial growth factor A Homo sapiens 166-170 9808085-8 1998 Furthermore, inhibition by genistein suggests that tyrosine phosphorylation was involved in the VEGF receptor upregulation. Genistein 27-36 vascular endothelial growth factor A Homo sapiens 96-100 10947125-5 2000 Genistein, Src tyrosine kinase inhibitor and H7, protein kinase C inhibitor, were used to inhibit VEGF mRNA expression. Genistein 0-9 vascular endothelial growth factor A Homo sapiens 98-102 10198191-5 1999 IL-1 beta-induced accumulations of VEGF mRNA in cardiac myocytes were abolished by the tyrosine kinase inhibitor genistein, whereas inhibition of protein kinase C (PKC) by staurosporin, calphostin C and phorbol ester-induced PKC depletion, and intracellular Ca2+ chelators did not affect the induction of VEGF mRNA by IL-1 beta. Genistein 113-122 vascular endothelial growth factor A Homo sapiens 35-39 10198191-5 1999 IL-1 beta-induced accumulations of VEGF mRNA in cardiac myocytes were abolished by the tyrosine kinase inhibitor genistein, whereas inhibition of protein kinase C (PKC) by staurosporin, calphostin C and phorbol ester-induced PKC depletion, and intracellular Ca2+ chelators did not affect the induction of VEGF mRNA by IL-1 beta. Genistein 113-122 vascular endothelial growth factor A Homo sapiens 305-309 9443437-6 1998 Prior administration of the tyrosine kinase inhibitors genistein or herbimycin A prevented VEGF/VPF-induced permeability. Genistein 55-64 vascular endothelial growth factor A Homo sapiens 91-95 9531578-12 1998 Protein tyrosine kinase and protein kinase C are involved in signal transduction leading to VEGF production, as shown by the inhibitory effects of genistein and GF 109203X. Genistein 147-156 vascular endothelial growth factor A Homo sapiens 92-96 9443437-6 1998 Prior administration of the tyrosine kinase inhibitors genistein or herbimycin A prevented VEGF/VPF-induced permeability. Genistein 55-64 vascular endothelial growth factor A Homo sapiens 96-99 35608747-0 2022 Molecular effects of genistein, as a potential anticancer agent, on CXCR-4 and VEGF pathway in acute lymphoblastic leukemia. Genistein 21-30 vascular endothelial growth factor A Homo sapiens 79-83 9572397-6 1998 Incubation with genistein, a protein tyrosine kinase inhibitor, for 3 h following seeding resulted in the reduction of the VEGF mRNA levels in highly confluent cultures but not in sparse cultures. Genistein 16-25 vascular endothelial growth factor A Homo sapiens 123-127 7540725-5 1995 We show here that genistein, an inhibitor of protein tyrosine kinase, blocks VEGF induction. Genistein 18-27 vascular endothelial growth factor A Homo sapiens 77-81 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Genistein 17-20 vascular endothelial growth factor A Homo sapiens 147-151 9255609-5 1997 While the tyrosine kinase inhibitor, genistein, blocked VEGF upregulation by activated tyrosine protein kinases, and the Ras inhibitor, N-Acetyl-S-trans-farnesyl-L-cysteine (AFC), eliminated VEGF expression in cells transformed by v-Ras, neither agent blocked upregulation by hypoxia or UV radiation. Genistein 37-46 vascular endothelial growth factor A Homo sapiens 56-60 9255609-5 1997 While the tyrosine kinase inhibitor, genistein, blocked VEGF upregulation by activated tyrosine protein kinases, and the Ras inhibitor, N-Acetyl-S-trans-farnesyl-L-cysteine (AFC), eliminated VEGF expression in cells transformed by v-Ras, neither agent blocked upregulation by hypoxia or UV radiation. Genistein 37-46 vascular endothelial growth factor A Homo sapiens 191-195 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Genistein 17-20 vascular endothelial growth factor A Homo sapiens 92-96 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Genistein 17-20 vascular endothelial growth factor A Homo sapiens 147-151 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Genistein 230-233 vascular endothelial growth factor A Homo sapiens 92-96 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Genistein 230-233 vascular endothelial growth factor A Homo sapiens 147-151 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Genistein 230-233 vascular endothelial growth factor A Homo sapiens 147-151 35608747-6 2022 After being treated with Genistein, the expression of VEGF in mRNA and protein levels was measured in MOLT-4 and Jurkat cells. Genistein 25-34 vascular endothelial growth factor A Homo sapiens 54-58 35608747-9 2022 After Genistein-treatment, surface expression levels of CXCR-4 were decreased, while VEGF secretion and mRNA expression levels were increased in MOLT-4 and Jurkat cells. Genistein 6-15 vascular endothelial growth factor A Homo sapiens 85-89 35608747-10 2022 CONCLUSIONS: The results suggest that Genistein may not be a reliable choice for the treatment of ALL; however, this different identified pattern can be useful for the recognition of VEGF and CXCR-4 modulators and thus for planning new treatments for leukemia and other VEGF related disorders. Genistein 38-47 vascular endothelial growth factor A Homo sapiens 183-187 33432829-3 2022 Compared with a casein-based placebo, 18 mo, of consumption of 19.2 g/day of whole soy protein isolate containing 24 mg genistein-reduced circulating testosterone and SHBG, but not free testosterone, and did not affect serum concentrations of estradiol, VEGF, IGF-1, IGFBP-3, IGF-1/IGFBP-3 ratio, soluble Fas, Fas-ligand, and sFas/Fas-ligand ratio. Genistein 120-129 vascular endothelial growth factor A Homo sapiens 254-258